The decision is part of J&J’s strategy to prioritize resources for the greatest impact and positions Laminar for success ...

Johnson & Johnson is selling key assets related to its Laminar program to a new startup, Jaguar LAA. This comes less than ...

Jaguar LAA, Inc. ("Jaguar"), a privately held medical device company, today announced the acquisition of assets related to the Laminar program, focused on addressing the left atrial appendage ("LAA") ...

Johnson & Johnson sold the left-atrial appendage system it paid $400 million for three years ago, abandoning plans to compete with Boston Scientific and Abbott.

Jaguar LAA, a newly formed medtech, has acquired assets that are part of Johnson & Johnson’s Afib device Laminar program for an undisclosed price. The Laminar device focuses on a catheter-based left ...

Johnson & Johnson is ending its left atrial appendage closure technology program. The New Brunswick, NJ-based company said it ...